At a glance
ClinicalIndex Comparison RecordN/ACompleted· 28 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study
In Brief
An observational study evaluating Bevacizumab for Breast Cancer. Completed, enrolled 28 participants across 12 sites.
Detailed Summary
This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesArgentina
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedOct 2010
Primary CompletionJul 2012
TodayJul 2026
First PostedOct 6, 2010
Enrollment StartJan 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.7 years ago
Interventions
Bevacizumabdrug
Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.